Platelet Aggregation InhibitorsTiclopidineAspirinPlatelet AggregationPlatelet Function TestsThrombosisHemorrhageBlood PlateletsPurinergic P2Y Receptor AntagonistsDrug Therapy, CombinationAnticoagulantsReceptors, Purinergic P2Y12ThienopyridinesPhenprocoumonCoronary ThrombosisPlatelet ActivationDipyridamoleThiophenesFibrinolytic AgentsAcute Coronary SyndromeStentsPlatelet Glycoprotein GPIIb-IIIa ComplexTreatment OutcomeAngioplasty, Balloon, CoronaryStrokeBleeding TimeWarfarinDrug-Eluting StentsMyocardial InfarctionTetrazolesThromboxane B2Postoperative HemorrhageRisk FactorsPlatelet CountSecondary PreventionTime FactorsThromboembolismPhosphodiesterase 3 InhibitorsAdenosine DiphosphateProspective StudiesPurinergic P2 Receptor AntagonistsPerioperative CareCoronary Artery DiseaseThrombocytopeniaDrug ResistanceSulfinpyrazonePurpura, ThrombocytopenicFollow-Up StudiesImmunoglobulin Fab FragmentsRecurrencePiperazinesRandomized Controlled Trials as TopicRisk AssessmentPercutaneous Coronary InterventionIschemic Attack, TransientHeparinPhenazopyridineAdministration, OralThromboxanesAcenocoumarolIntracranial ThrombosisIntracranial HemorrhagesCerebrovascular DisordersCerebral HemorrhageRetrospective StudiesCoronary DiseaseEmbolismBrain IschemiaHematomaPyridinesPlatelet AdhesivenessPlatelet Membrane GlycoproteinsDilazepGraft Occlusion, VascularAryl Hydrocarbon HydroxylasesPurpura, Thrombocytopenic, IdiopathicEmbolism, CholesterolDose-Response Relationship, DrugThrombelastographyCardiovascular AgentsDrug InteractionsCardiovascular DiseasesCoronary RestenosisCarotid Artery ThrombosisCoronary AngiographyThrombolytic TherapyPeripheral Vascular DiseasesAntithrombinsInternational Normalized RatioProsthesis DesignBlood Loss, SurgicalP-SelectinThromboxane A2Blood CoagulationPractice Guidelines as TopicDrug Administration ScheduleRegistriesDouble-Blind MethodIntracranial EmbolismSirolimus